StockData

Vanda Pharmaceuticals Inc. (VNDA) income statement

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3059% below fair value
$3.44−0.23 (-6.13%)

Close on Nov 20, 2026Market cap $208.32MP/E –Yield –

Vanda Pharmaceuticals Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
93.6%
Operating margin
-77.6%
Net margin
-119.9%
Return on equity, FY2025
-50.9%

Financial strength

Current ratio
1.54
Debt to equity
–
Debt to assets
–
Cash to current liabilities
40.0%

Valuation

P/E ratio
–
Price to sales
0.91
Price to book
1.04
Dividend yield
–

See a number that looks wrong?